Research Achievements - Other -

骨髄腫細胞において低酸素で上昇するコーディング・ノンコーディング遺伝子の網羅的探索とその機能解析

池田翔, 北舘明宏, 阿部史人, 小林敬宏, 高橋直人, 田川博之

International Journal of Myeloma (Web)   7 ( 1 ) 54 - 54   2017.04

J-GLOBAL

Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum.

Yokoyama H, Takahashi N, Katsuoka Y, Inomata M, Ito T, Meguro K, Kameoka Y, Tsumanuma R, Murai K, Noji H, Ishizawa K, Ito S, Onishi Y, Harigae H, Tohoku Hematology Forum

International Journal of Hematology   105 ( 5 ) 606 - 613   2017.02

DOI

Clinicopathological characteristics of malignant lymphoma in patients with hepatitis C virus infection in the Tohoku district in Eastern Japan.

Tajima K, Takahashi N, Ishizawa K, Murai K, Akagi T, Noji H, Sasaki O, Wano M, Itoh J, Kato Y, Shichishima T, Harigae H, Ishida Y, Tohoku Hematology Forum

Leuk Lymphoma.   58 ( 6 ) 1509 - 1511   2017.01

DOI

[Refractory CD20-positive peripheral T-cell lymphoma showing loss of CD20 expression after rituximab therapy and gain of CD20 expression after administration of vorinostat and gemcitabine].

Teshima K, Ohyagi H, Kume M, Takahashi S, Saito M, Takahashi N

[Rinsho ketsueki] The Japanese journal of clinical hematology ( The Japanese Society of Hematology )  58 ( 11 ) 2227 - 2231   2017

<p>A 79-year-old male patient presented with systemic lymphadenopathy. A lymph node biopsy revealed effacement of the normal nodal architecture with diffuse proliferation of medium-sized atypical lymphoid cells. Southern blot analyses demonstrated rearrangement of the T-cell receptor gene but not the immunoglobulin heavy chain gene. He was diagnosed with CD20-positive peripheral T-cell lymphoma (PTCL), NOS. Although he achieved partial remission after six cycles of R-CHOP, he relapse occurred after 2 months. CD20-negative conversion was confirmed in the lymph node, which was positive for CCR4, and the skin at the time of relapse. The patient received the GDP regimen as salvage therapy with the addition of vorinostat for skin involvement; however, he failed to respond, and the disease systemically progressed. Furthermore, he also exhibited progression in the skin after stopping vorinostat due to hematologic toxicity. A lymph node biopsy at progression revealed CD20 re-expression by immunohistochemistry. At progression, the patient received mogamulizumab but failed to respond, and he died owing to disease progression 8 months after relapse. In this case, we demonstrated CD20-negative conversion following rituximab and CD20-positive reversion after using vorinostat and gemcitabine.</p>

DOI PubMed

Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis

FUJISHIMA Masumi, TAKAHASHI Naoto, FUJISHIMA Naohito, KITADATE Akihiro, GUO Yongmei, WATANABE Atsushi, UBUKAWA Kumi, NARA Miho, YOSHIOKA Tomoko, KAMEOKA Yoshihiro

Rinsho Ketsueki ( The Japanese Society of Hematology )  58 ( 7 ) 743 - 748   2017

<p>A 64-year-old woman was admitted to our hospital to undergo allogeneic stem cell transplantation. She was diagnosed with polycythemia vera with a JAK2 V617F mutation 7 years ago. She was administered ruxolitinib for splenomegaly two years prior to admission but this was discontinued because of progressive pancytopenia. One months after cessation of ruxolitinib, she developed acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis. Although she achieved complete remission after induction therapy, 8-finger-breadth splenomegaly remained below the left costal margin. Ruxolitinib was re-administered following two courses of consolidation therapy. She underwent unrelated peripheral blood stem cell transplantation. Ruxolitinib was administered until the day before transplantation, and the spleen was palpated in 4-finger breadth below costal arc. Neutrophil engraftment was achieved 13 days after transplantation. In allogeneic stem cell transplantation, splenomegaly is one of the risk factors for engraftment failure and/or therapy-related mortality. Hence, a smaller spleen size can theoretically improve the outcome after transplantation. The administration of ruxolitinib prior to transplantation may have contributed to engraftment with a non-invasive reduction in the size of the spleen.</p>

DOI PubMed

TAFRO Syndrome with Bilateral Adrenal Hemorrhage

Ito F, Kameoka Y, Nara M, Ubukawa K, Fujishima M, Yoshioka T, Fujishima N, Takahashi N

Nihon Naika Gakkai Zasshi.   106 ( 2 ) 288 - 294   2017

TAFRO Syndrome with Bilateral Adrenal Hemorrhage

Ito Fumiko, Kameoka Yoshihiro, Nara Miho, Ubukawa Kumi, Fujishima Masumi, Yoshioka Tomoko, Fujishima Naohito, Takahashi Naoto

Nihon Naika Gakkai Zasshi ( The Japanese Society of Internal Medicine )  106 ( 2 ) 288 - 294   2017

DOI